SCHEMBL734612

SCHEMBL734612

COC(=O)C(CCOCc1ccccc1)N1CCN(c2ccc(C(F)(F)F)cc2)CCC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 8/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 2/20 0.45
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
HTT P42858 2/20 0.42
POLB P06746 1/20 0.42
LDHA P00338 1/20 0.41
LDHB P07195 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTR1A P08908 1/20 0.40
GAA P10253 2/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
RECQL P46063 1/20 0.40
LIPG Q9Y5X9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734611 1.00 MAPT (0.47) MAPTSMN1; SMN2HPGDLMNAMEN1
SCHEMBL734773 0.91 HSD17B10 (0.47) MAPTSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL734350 0.91 HSD17B10 (0.47) MAPTSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL734349 0.91 HSD17B10 (0.47) MAPTSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL735128 0.90 CHRM4 (0.44) MEN1KMT2AALDH1A1
SCHEMBL735127 0.90 CHRM4 (0.44) MEN1KMT2AALDH1A1
SCHEMBL735444 0.85 CHRM4 (0.46) LMNAALDH1A1NPSR1
SCHEMBL735443 0.85 CHRM4 (0.46) LMNAALDH1A1NPSR1
SCHEMBL735105 0.84 LMNA (0.46) MAPTSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL735104 0.84 LMNA (0.46) MAPTSMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 MAPT 4751/4885SMN1; SMN2 4455/4885HPGD 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.